OncoDxRx’s Post

Situational awareness and drug response prediction in cancer treatment is critical to maintaining the therapeutic advantage. Yet the increasing heterogeneity of tumor is constantly challenging this advantage. The evolving of drug resistance, in particular targeted therapy, is significantly contributing to shifting cancer battlefield supremacy. High proliferation and the constant evolution of tumor clones in terms of dynamics, kinetics, immunoediting, immunosuppression and immune escaping increases the level of cancer threat day by day. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing

PGA: A Revolutionary Gene Expression Test for Personalized Cancer Treatment "You are allergic to your chemotherapy. We are going to try a newer drug.” This is a common scene for many cancer patients. Patients are often seeking for treatments suitable for their body, their cancer, their pocket and their QOL! OncoDxRx developed a revolutionary assay, PGA (Patient-derived Gene expression-informed Anticancer drug efficacy), to correlate drug efficacies with the patient’s gene expression signature. When the patient’s gene expression probe has drug matches, then these drugs can be interpreted as hits that are most likely to benefit the patient.   PGA is an innovative liquid biopsy technology specifically developed for gene-to-drug mapping. The assay operates by in vitro gene profiling and in silico computation. This allows clinicians to make accurate diagnosis and informed decisions about the best treatment for each patient. PGA can predict individual patient responses to the existing approx. 700 cancer drugs. By predicting how patients will respond to drugs individually, the test allows therapy to be tailored in a way that is most effective while minimizing side effects. In conclusion, PGA is a pioneering technique that showcases the power of gene expression in transforming medical treatment. By enabling more accurate diagnoses and personalized treatment, it holds the potential to improve patient stratification, thereby enhancing the overall quality of healthcare. The future of personalized cancer treatment indeed seems brighter with the advent of disruptive tests like PGA. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

🔎𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 Evox Therapeutics Ltd Targets protein misfolding in diseases like Alzheimer's and cancer. Sana Biotechnology, Inc. Uses gene editing for curative cell therapies in blood diseases. Ikena Oncology Targets unique metabolic pathways in hard-to-treat cancers. Pionyr Immunotherapeutics Develops next-gen immunotherapies to supercharge a patient's immune system against cancer. BlueWillow Biologics, Inc. Pioneering a new approach to target RNA for treating neurodegenerative diseases like ALS. Absci Uses AI to speed up drug discovery, leading to faster development of new treatments. Let me know in the comments any other biotech's to watch out for 👇🏼 #biotech #research #drugdevelopment #drugdiscovery

Big confluence of factors driving an ever bigger market opportunity. The War on Cancer will never end, and never not keep attracting outsized investment up and down the stack. "The market is primarily driven by factors such as an increase in technological advancements, a rise in cancer incidences, and improvements in personalized medicine and cell and gene therapies, which are starting new approaches for developing new treatments for cancer-like diseases. Moreover, an increase in funding from pharmaceutical and biotech companies, non-profit organizations, and CROs for oncology clinical trials is further supporting market growth and the development of advanced products to gain substantial market share." #5ForcesofHCT #Pharma #Cancer #ClinicalTrials #Biotech #Biopharma https://lnkd.in/gTEyCcUz

The Overlooked Simplicity in Biomarker Discovery I'm all for large omics studies and the utility they have in understanding the mechanism of action, especially in the preclinical setting. But, in the early stages of clinical trials, the heterogeneity (often multiple indications and disease stages) and high costs associated with biomarker mining challenge its budget effectiveness and statistical value. Many of the features in a comprehensive gene assay are not of appropriate prevalence in the population or have enough dynamic range to make it a robust biomarker. Historical successes, such as the identification of PSA for prostate cancer, exemplify the potential of targeted, hypothesis-driven research over complex methodologies. Embracing simplicity could lead to more scientifically and economically efficient discoveries, aligning closely with clinical utility and real-world applicability. #biomarkerdiscovery #biomarkers #clinicaltrials ---- Hi, I'm Josie, a strategic biomarker consultant. I provide advice to therapeutics companies on preclinical and clinical biomarker strategy. Follow me to hear more of this or schedule a call with me for a free intro chat.

CAR T-cell therapy, formerly known as T -bodies, was first elucidated in 1987 in Japan by Yoshihisa Kuwana and coworkers by combining parts of an antibody with the TCR. In 1989, the concept of CAR T was independently illustrated by Gideon Gross and Zelig Eshhar in Israel. CAR T-cell therapy is a type of immunotherapy where a person’s T cells (a type of immune cell) are genetically modified in a laboratory to selectively target and destroy cancer cells. Now CAR T-cell therapy has evolved steadily over the last few decades, going through five generations since its inception to the most recent and advanced fifth generation, which offers improved therapeutic outcomes with lower toxicity. In October 2023, India’s regulatory body, the Central Drugs Standard Control Organization (CDSCO), approved NexCAR19 as India’s first CAR-T cell therapy. The approval was based on results from two small clinical trials conducted in India involving 64 people with advanced lymphoma or leukemia. This groundbreaking therapy, known as NexCAR19, was developed by ImmunoACT, a company incubated at the Indian Institute of Technology Bombay (IITB) and Tata Memorial Hospital. The President of India, launched India’s first home-grown gene therapy for cancer at IIT Bombay on April 4 2024. Six CAR T cell therapies have been approved by US FDA till date. KYMRIAH YESCARTA TECARTUS  BREYANZI  ABECMA CARVYKTI Hey, This is Ravikant 😀 Like and follow for such contents 👍🏻 #Lifescience #biotech #CARTCELL #Pharma #innovation

OncoDxRx’s Advanced Thinking and Approaches Cancer cells do not exist in isolation, and much of their biological behavior is driven by interactions with other cells in the tumor microenvironment. To dissect these interactions, OncoDxRx is focusing on liquid biopsy transcriptomics. We start our development from patient-derived specimens to ensure that the gene expression patterns we discover are relevant to patients themselves. As we are exceling in our ability to reveal and capture the mechanisms underlying these behaviors, we can quickly translate our findings from bench to bedside to community. Our findings led to the breakthrough PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) test that allowed us to match each individual patient to certain cancer drugs, which is paramount in our efforts to improve treatment options and patient outcomes, especially for those patients who are not responding to their current therapies, i.e., non-responders. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

🔬5 clinical trials to watch in 2024     Exciting new #ClinicalTrials promise a breakthrough in treating complex diseases in 2024.     Here are a few trials I'm excited to share with you:    1️⃣Gilead Sciences  They are testing its cancer drug Trodelvy in the Evoke-01 lung cancer trial, hoping for a big win in a tough disease.    2️⃣Sanofi  They are conducting trials for tolebrutinib, a promising drug for multiple sclerosis, despite recent challenges faced by similar drugs known as BTK inhibitors.     3️⃣Pfizer  Pfizer is developing a gene therapy for Duchenne muscular dystrophy, conducting a Phase 3 trial with hopes to outperform Sarepta Therapeutics' Elevidys.     4️⃣Moderna  Advancing mRNA technology, Moderna develops a flu vaccine, with the potential for a combination flu and COVID-19 vaccine.    5️⃣Beam Therapeutics  They launched a trial for a sickle cell treatment using "base editing," a CRISPR derivative, aiming to refine gene editing with potentially safer and more precise outcomes.    Which trial results do you expect to witness the most? Share in the comments.

DPU Pharmacy successfully set the stage rolling with the inaugural session of the 4th international faculty development program (4th iFDP) on Emerging Trends in Oncology: Therapeutics and Diagnostics , on 23rd March 2024. Dr. Vikram Gota, Professor, Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Chief Guest and Keynote speaker enlightened the delegates who had gathered from various institutions across the country through the virtual platform on the Readiness for Gene and cell-based therapies in India. The session delved into the transformative potential of gene and cell therapies, shedding light on their mechanisms, targeted diseases, and the global landscape. Dr. Gota detailed the approaches for gene and cell therapy, highlighting the innovative techniques used to tackle genetic disorders and cancer. The discussion transitioned into the Indian scenario, comparing it with global standards and exploring India's capacity and readiness to adopt these advanced treatments. Through a SWOT analysis, Dr. Gota outlined the strengths, such as India's robust biotech research base, and weaknesses, including regulatory hurdles. The session set the stage for meaningful deliberations in Oncology research. Join us for the, Second session on 30 March 2024. #dpu#oncology#gene therapy#CAR-T

Switzerland is a biotech powerhouse, with established players in every stage along the way, from education to manufacturing going through research and development. Taking into account the country’s success last year, Switzerland is undoubtedly on an upward trajectory. Biotech companies in Switzerland are heavily invested in developing new cancer treatments and immunotherapies, with pharma giants Novartis and Roche leading this space. Switzerland is also a hub for gene and cell therapy development and contributes to research on therapies targeting the aging process and age-related diseases, exemplified by Rejuveron Life Sciences’ impressive portfolio in the field. This article in Labiotech explores eighteen biotech companies based in Switzerland worth keeping an eye on: https://lnkd.in/ehnKdaEx #Switzerland #Biotech #Talent